Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, a… Read more
Gujarat Themis Biosyn Limited (GUJTHEM) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.12 Billion INR
Based on the latest financial reports, Gujarat Themis Biosyn Limited (GUJTHEM) has total liabilities worth ₹1.12 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gujarat Themis Biosyn Limited - Total Liabilities Trend (2022–2025)
This chart illustrates how Gujarat Themis Biosyn Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gujarat Themis Biosyn Limited Competitors by Total Liabilities
The table below lists competitors of Gujarat Themis Biosyn Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acusensus Ltd
AU:ACE
|
Australia | AU$43.22 Million |
|
Tunas Baru Lampung Tbk
JK:TBLA
|
Indonesia | Rp20.62 Trillion |
|
Ekovest Bhd
KLSE:8877
|
Malaysia | RM8.28 Billion |
|
Zig Sheng Industrial Co Ltd
TW:1455
|
Taiwan | NT$3.39 Billion |
|
Guangdong Hongming Intelligent Joint Stock Co. Ltd.
SHE:301105
|
China | CN¥90.52 Million |
|
China Electric Manufacturing Corp
TW:1611
|
Taiwan | NT$960.99 Million |
|
Dah San Electric Wire & Cable Co Ltd
TW:1615
|
Taiwan | NT$1.82 Billion |
|
SV Investment Corporation
KQ:289080
|
Korea | ₩24.78 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Gujarat Themis Biosyn Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gujarat Themis Biosyn Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gujarat Themis Biosyn Limited (2022–2025)
The table below shows the annual total liabilities of Gujarat Themis Biosyn Limited from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹529.31 Million | +168.18% |
| 2024-03-31 | ₹197.37 Million | +14.87% |
| 2023-03-31 | ₹171.82 Million | -10.41% |
| 2022-03-31 | ₹191.79 Million | -- |